EA202190749A1 - Способы комбинированной терапии - Google Patents

Способы комбинированной терапии

Info

Publication number
EA202190749A1
EA202190749A1 EA202190749A EA202190749A EA202190749A1 EA 202190749 A1 EA202190749 A1 EA 202190749A1 EA 202190749 A EA202190749 A EA 202190749A EA 202190749 A EA202190749 A EA 202190749A EA 202190749 A1 EA202190749 A1 EA 202190749A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
formula
therapy methods
combined therapy
kras
Prior art date
Application number
EA202190749A
Other languages
English (en)
Inventor
Ларс Даниэль Энгстром
Рут Вэй Аранда
Питер Олсон
Джеймс Гейл Кристенсен
Джилл Халлин
Original Assignee
Мирати Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мирати Терапьютикс, Инк. filed Critical Мирати Терапьютикс, Инк.
Publication of EA202190749A1 publication Critical patent/EA202190749A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способам комбинированной терапии для лечения раковых заболеваний, связанных с KRas G12C. В частности, настоящее изобретение относится к способам лечения рака у субъекта, нуждающегося в этом, включающим введение субъекту терапевтически эффективного количества комбинации универсального ингибитора семейства ErbB и ингибитора KRAS G12C формулы (I), формулы I-A или формулы I-B, к фармацевтическим композициям, содержащим терапевтически эффективные количества ингибиторов, к наборам, содержащим композиции, и к способам их применения.
EA202190749A 2018-09-10 2019-09-09 Способы комбинированной терапии EA202190749A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729189P 2018-09-10 2018-09-10
PCT/US2019/050227 WO2020055756A1 (en) 2018-09-10 2019-09-09 Combination therapies

Publications (1)

Publication Number Publication Date
EA202190749A1 true EA202190749A1 (ru) 2021-07-09

Family

ID=69778045

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190749A EA202190749A1 (ru) 2018-09-10 2019-09-09 Способы комбинированной терапии

Country Status (13)

Country Link
US (1) US20220054491A1 (ru)
EP (1) EP3849538A4 (ru)
JP (1) JP7546548B2 (ru)
KR (1) KR20210075981A (ru)
CN (1) CN112955137A (ru)
AU (1) AU2019340366A1 (ru)
CA (1) CA3112043A1 (ru)
EA (1) EA202190749A1 (ru)
IL (1) IL281344A (ru)
MX (1) MX2021002805A (ru)
SG (1) SG11202102377YA (ru)
WO (1) WO2020055756A1 (ru)
ZA (1) ZA202102015B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021043322A1 (zh) * 2019-09-06 2021-03-11 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN112694475A (zh) * 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
WO2021219072A1 (zh) * 2020-04-30 2021-11-04 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
CN115996717A (zh) * 2020-06-25 2023-04-21 托雷莫治疗股份公司 用于治疗癌症的cbp/p300溴结构域抑制剂和kras抑制剂的组合
CN116568306A (zh) * 2020-12-08 2023-08-08 基因泰克公司 用于治疗实体瘤的包含krasg12c抑制剂和egfr抑制剂的方法和组合物
WO2022148421A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
CN117460737A (zh) * 2021-07-05 2024-01-26 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575413A1 (en) * 2009-12-11 2019-12-04 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
CA3182876A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017201161A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
HRP20230377T1 (hr) * 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
US10647715B2 (en) * 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020055761A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7546549B2 (ja) * 2018-09-10 2024-09-06 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
JP2022500388A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
WO2020055760A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (es) * 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
CA3152025A1 (en) * 2019-09-24 2021-04-01 David BRIERE Combination therapies
WO2022056307A1 (en) * 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
US20230383359A1 (en) * 2020-10-23 2023-11-30 Mirati Therapeutics, Inc. Methods for treatment of lung cancers
JP2024513492A (ja) * 2021-04-08 2024-03-25 ミラティ セラピューティクス、インコーポレイテッド がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法

Also Published As

Publication number Publication date
EP3849538A4 (en) 2022-06-29
MX2021002805A (es) 2021-07-15
CN112955137A (zh) 2021-06-11
ZA202102015B (en) 2023-05-31
CA3112043A1 (en) 2020-03-19
US20220054491A1 (en) 2022-02-24
JP2022500379A (ja) 2022-01-04
AU2019340366A1 (en) 2021-04-01
WO2020055756A1 (en) 2020-03-19
JP7546548B2 (ja) 2024-09-06
KR20210075981A (ko) 2021-06-23
EP3849538A1 (en) 2021-07-21
SG11202102377YA (en) 2021-04-29
IL281344A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
EA202190749A1 (ru) Способы комбинированной терапии
MX2022000711A (es) Inhibidores de parp1.
CR20200518A (es) Piridozinonas como inhibidores de parp7
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201790088A1 (ru) Ингибиторы syk
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2024006094A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA202190125A1 (ru) ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl